| __timestamp | Axsome Therapeutics, Inc. | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 15746000 |
| Thursday, January 1, 2015 | 2419289 | 13392000 |
| Friday, January 1, 2016 | 6343648 | 9290000 |
| Sunday, January 1, 2017 | 7206691 | 7672000 |
| Monday, January 1, 2018 | 9351522 | 15293000 |
| Tuesday, January 1, 2019 | 13598030 | 22648000 |
| Wednesday, January 1, 2020 | 28896749 | 21864000 |
| Friday, January 1, 2021 | 66646205 | 37318000 |
| Saturday, January 1, 2022 | 159253661 | 48130000 |
| Sunday, January 1, 2023 | 323123000 | 108146000 |
| Monday, January 1, 2024 | 411359000 |
Unleashing insights
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Madrigal Pharmaceuticals, Inc. and Axsome Therapeutics, Inc. from 2014 to 2023. Over this period, Axsome Therapeutics has seen a staggering increase in SG&A expenses, growing by over 23,000% from 2014 to 2023. In contrast, Madrigal Pharmaceuticals experienced a more modest increase of around 587% during the same timeframe.
By 2023, Axsome's SG&A expenses reached approximately three times that of Madrigal's, highlighting a significant divergence in their financial strategies. This trend may reflect Axsome's aggressive expansion and investment in marketing and administrative capabilities. Understanding these financial dynamics provides valuable insights into the strategic priorities and growth trajectories of these two innovative companies.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Selling, General, and Administrative Costs: BeiGene, Ltd. vs Madrigal Pharmaceuticals, Inc.
Bio-Techne Corporation or Madrigal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Alpine Immune Sciences, Inc.
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or CymaBay Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Madrigal Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Madrigal Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Axsome Therapeutics, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.